Summary
This manuscript reviews the means by which live attenuated varicella vaccine offers protection against varicella and zoster. It is accepted that although varicella is usually a mild illness, complications leading to morbidity and mortality are significant and the disease is worth preventing. The vaccine offers close to 100% protection from severe chickenpox and 90% protection from illness. Waning of immunity after vaccination, particularly in children, has not been a significant problem. Ways in which vaccination may decrease the incidence and severity of zoster include the following. Vaccine virus may be less likely to establish latency and to be able to reactivate than wild type virus. In addition, by selective immunization of certain hosts such as HIV-infected children whose immune systems are still relatively intact and individuals with latency due to wild type virus to boost the cell-mediated immune response to the virus, zoster may be decreased. Varicella vaccine is predicted to have a major impact on the epidemiology of varicella and zoster in countries with high vaccine uptake.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Arvin A, Gershon A (1996) Live attenuated varicella vaccine. Annu Rey Microbiol 50: 59–100
Asano Y, Albrecht P, Vujcic LK, Quinnan GV Jr, Kawakami K, Takahashi M (1983) Five-year follow-up study of recipients of live varicella vaccine using enhanced neutralization and fluorescent antibody membrane antigen assays. Pediatrics 72: 291–294
Asano Y, Suga S, Yoshikawa T, Kobayashi H, Yazaki T, Shibata M, Tsuzuki K, Ito S (1994) Experience and reason: twenty year follow up of protective immunity of the Oka live varicella vaccine. Pediatrics 94: 524–526
Berger R, Luescher D, Just M (1984) Enhancement of varicella-zoster-specific immune responses in the elderly by boosting with varicella vaccine. J Infect Dis 149: 647
Broyer M, Tete MT, Guest G, Gagnadoux MF, Rouzioux C (1997) Varicella and zoster in children after kidney trasplantation: long term results of vaccination. Pediatrics 99: 35–39
Brunell PA, Taylor-Wiedeman J, Geiser CF, Frierson L, Lydick E (1986) Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox. Pediatrics 77: 53–56
Centers for Disease Control (1999) Prevention of varicella. Morb Mort Wkly Rep 48: 1–6
Centers for Disease Control (1999) Varicella-related deaths. Florida Morb. Mort Wkly Rep 48: 379–381
Derryck A, LaRussa P, Steinberg S, Capasso M, Pitt J, Gershon A (1998) Varicella and zoster in children with human immunodeficiency virus infection. Ped Infect Dis J 17: 931–933
Gershon A (1995) Varicella-zoster virus: prospects for control. Adv Ped Infect Dis 10: 93–124
Gershon A, LaRussa P, Steinberg S, Lo SH, Mervish N, Meier P (1996) The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. J Infect Dis 173: 450–453
Gershon A, Mervish N, LaRussa P, Steinberg S, Lo S-H, Hodes D, Fikrig S, Bonagura V, Bakshi S (1997) Varicella-zoster virus infection in children with underlying HIV infection. J Infect Dis 175: 1496–1500
Gershon AA, Steinberg S, LaRussa P, Hammerschlag M, Ferrara A, NIAIDCollaborative-Varicella-Vaccine-Study-Group (1988) Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis 158: 132–137
Hardy IB, Gershon A, Steinberg S, LaRussa P, et al. (1991) The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. N Engl J Med 325: 1545–1550
Johnson C, Stancin T, Fattlar D, Rome LP, Kumar ML (1997) A long-term prospective study of varicella vaccine in healthy children. Pediatrics 100: 761–766
Levin M, Gershon A, Weinberg A, Blanchard S, Wells B, Nowak B, ACTG 265 Protocol T (1999) Administration of varicella vaccine to HIV-infected children. In: Retroviral Conference, Chicago, December 1999
Levin M, Murray M, Zerbe G, White CJ, Hayward AR (1994) Immune responses of elderly person 4 years after receiving a live attenuated varicella vaccine. J Infect Dis 170: 522–526
Shapiro ED, LaRussa PS, Steinberg S, Gershon A (1998) Protective efficacy of varicella vaccine. In: 36th Annual Meeting, Infectious Diseases Society of America, Denver, CO
Takahashi M, Gershon A (1994) Varicella Vaccine. In: Mortimer E, Plotkin S (eds) Vaccines, 2nd ed. Saunders, Philadelphia, pp 387–417
White CJ (1996) Clinical trials of varicella vaccine in healthy children. Infect Dis N Am 10: 595–608
White CJ (1997) Varicella-zoster virus vaccine. Clin Infect Dis 24: 753–763
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Wien
About this paper
Cite this paper
Gershon, A.A. (2001). The current status of live attenuated varicella vaccine. In: Gershon, A.A., Arvin, A.M., Calisher, C.H. (eds) Immunity to and Prevention of Herpes Zoster. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6259-0_1
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6259-0_1
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83555-5
Online ISBN: 978-3-7091-6259-0
eBook Packages: Springer Book Archive